About US
Contact us
-
New ulcerative colitis data could help Pfizer's Xeljanz pick up the paceRheumatoid arthritis therapyXeljanzhasn't gotten off to the start Pfizer ($PFE) hoped, but new indications could give it a boost. On that front, the company reported positive results on Mondayfrom a p2015/9/22
-
Bayer sets up triumvirate of managers to run slimmed-down operationChange is coming forBayer--and with it, change at the top. The German pharma has outlined its plans for retooling, post-plastics division divestment--and they involve three operational arms, each head2015/9/22
-
Novartis CEO stands by emerging markets even as China economy continues to weakenChina's economy is a mess and other emerging markets are flailing about as well. So what is pharma CEO to do if they have bet big on growth in the EM realm? Keep on keeping on, says Novartis ($NVS) CE2015/9/21
-
UPDATED: FDA asks Pfizer for Zoloft label update highlighting birth defect risksFor years, Pfizer ($PFE) has shrugged off claims that its antidepressantZoloftcauses heart defects in newborns, fighting a raft of litigation alleging that the company did not adequately warn pregnant2015/9/21
-
Celgene's Abraxane takes another hit from cost-effectiveness gatekeepersCelgene's ($CELG)Abraxanecan't catch a break in England. Soon after losing coverage for pancreatic cancer on the country's dedicatedCancer Drugs Fund, the treatment got another thumbs-down from its of2015/9/18
-
Lilly, BI's Jardiance posts 'amazing' 14% reduction in major CV eventsSince Eli Lilly ($LLY) andBoehringer Ingelheimannounced that theirSGLT2med,Jardiance, had become the first to show it could lower the risk of major cardiovascular events, the question on the minds of2015/9/18
-
Victoza tops Sanofi's Lyxumia in trial, adding to Novo's GLP-1 arsenalCompetition is heating up in the GLP-1 diabetes market, and Novo Nordisk ($NVO) is doing what it can to line up data behind its long-dominant drug,Victoza. The latest: A study pitting the brand agains2015/9/17
-
BMS' Opdivo guns for kidney cancer nod with FDA 'breakthrough' tagLast July, Bristol-Myers Squibb ($BMY) put an early end to a late-stage study that showed its immunotherapy drug,Opdivo, looked good in patients with advancedkidney cancer. And now, it's one step clos2015/9/17
-
Novartis priced Entresto on par with results, new cost watchdog saysA new U.S. cost-effectiveness watchdog has now weighed in on three of the most hotly anticipated drug launches of 2015. And so far, pharma has scored just one out of three. Last week, the Institute f2015/9/16
-
Novo racks up Tresiba data for impending mano a mano with Sanofi's ToujeoNovo Nordisk is out trumpeting new data on its next-gen basal insulinTresibaand a combo med, Xultophy. New studies to brag about are always good things. But they're particularly well-timed now, with t2015/9/16